These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30184433)

  • 1. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
    Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
    ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
    LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
    Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.
    Patel AG; De Lorenzo SB; Flatten KS; Poirier GG; Kaufmann SH
    Clin Cancer Res; 2012 Mar; 18(6):1655-62. PubMed ID: 22291137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks.
    Velagapudi UK; Rouleau-Turcotte É; Billur R; Shao X; Patil M; Black BE; Pascal JM; Talele TT
    Biochem J; 2024 Mar; 481(6):437-460. PubMed ID: 38372302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
    Gojo I; Beumer JH; Pratz KW; McDevitt MA; Baer MR; Blackford AL; Smith BD; Gore SD; Carraway HE; Showel MM; Levis MJ; Dezern AE; Gladstone DE; Ji JJ; Wang L; Kinders RJ; Pouquet M; Ali-Walbi I; Rudek MA; Poh W; Herman JG; Karnitz LM; Kaufmann SH; Chen A; Karp JE
    Clin Cancer Res; 2017 Feb; 23(3):697-706. PubMed ID: 27503200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
    Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
    J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols.
    Maluchenko NV; Feofanov AV; Studitsky VM
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial poly(ADP-ribose) polymerase: The Wizard of Oz at work.
    Brunyanszki A; Szczesny B; Virág L; Szabo C
    Free Radic Biol Med; 2016 Nov; 100():257-270. PubMed ID: 26964508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial PARP1 regulates NAD
    Lee JH; Hussain M; Kim EW; Cheng SJ; Leung AKL; Fakouri NB; Croteau DL; Bohr VA
    Exp Mol Med; 2022 Dec; 54(12):2135-2147. PubMed ID: 36473936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,25-Dihydroxyvitamin D
    De Silva WGM; Sequeira VB; Yang C; Dixon KM; Holland AJA; Mason RS; Rybchyn MS
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, biological evaluation of novel piperidine-based derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
    Lin C; Liu C; Hu P; Zou Z; Sun G
    Bioorg Chem; 2024 Jul; 148():107455. PubMed ID: 38772289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Veliparib exerts protective effects in intracerebral hemorrhage mice by inhibiting the inflammatory response and accelerating hematoma resolution.
    Fu Y; Liu R; Zhao Y; Xie Y; Ren H; Wu Y; Zhang B; Chen X; Guo Y; Yao Y; Jiang W; Han R
    Brain Res; 2024 Sep; 1838():148988. PubMed ID: 38729332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) mediates bioenergetic defects and redox imbalance in neurons following oxygen and glucose deprivation.
    Hossain MI; Lee JH; Gagné JP; Khan J; Poirier GG; King PH; Dawson VL; Dawson TM; Andrabi SA
    FASEB J; 2024 Mar; 38(6):e23556. PubMed ID: 38498348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.
    Nebenzahl-Sharon K; Sharf R; Amer J; Shalata H; Khoury-Haddad H; Sohn SY; Ayoub N; Hearing P; Kleinberger T
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31315986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.
    Pirinen E; Cantó C; Jo YS; Morato L; Zhang H; Menzies KJ; Williams EG; Mouchiroud L; Moullan N; Hagberg C; Li W; Timmers S; Imhof R; Verbeek J; Pujol A; van Loon B; Viscomi C; Zeviani M; Schrauwen P; Sauve AA; Schoonjans K; Auwerx J
    Cell Metab; 2014 Jun; 19(6):1034-41. PubMed ID: 24814482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
    Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
    Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
    [No Abstract]   [Full Text] [Related]  

  • 19. Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury.
    Nehme J; Mesilmany L; Varela-Eirin M; Brandenburg S; Altulea A; Lin Y; Gaya da Costa M; Seelen M; Hillebrands JL; van Goor H; Saab R; Akl H; Prevarskaya N; Farfariello V; Demaria M
    Nat Aging; 2024 Jun; 4(6):771-782. PubMed ID: 38724734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    Bartelink IH; Prideaux B; Krings G; Wilmes L; Lee PRE; Bo P; Hann B; Coppé JP; Heditsian D; Swigart-Brown L; Jones EF; Magnitsky S; Keizer RJ; de Vries N; Rosing H; Pawlowska N; Thomas S; Dhawan M; Aggarwal R; Munster PN; Esserman LJ; Ruan W; Wu AHB; Yee D; Dartois V; Savic RM; Wolf DM; van 't Veer L
    Breast Cancer Res; 2017 Sep; 19(1):107. PubMed ID: 28893315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.